Does Osteoarthritis Affect Life Expectancy?

Osteoarthritis does not dramatically shorten life on its own, but the chain of consequences it sets off, particularly reduced physical activity and increased cardiovascular risk, can modestly lower life expectancy. Large meta-analyses generally find that having osteoarthritis raises the overall risk of dying earlier by somewhere around 10 to 20 percent, though the numbers vary depending on which joints are affected and whether the disease causes pain or just shows up on an X-ray. The story is less about cartilage wearing away and more about what happens to the rest of your body when a major joint stops working well.

What the Mortality Numbers Actually Show

Researchers have spent decades trying to pin down whether osteoarthritis shortens life, and the honest answer is that the signal is real but not enormous. A meta-analysis pooling data from multiple studies found no statistically significant increase in all-cause mortality for people with radiographic osteoarthritis or symptomatic osteoarthritis when analyzed broadly.¹ Two earlier traditional meta-analyses focused on knee osteoarthritis found increases of about 21 to 24 percent in the risk of death, but neither reached statistical significance.² A large U.S. cohort study using the National Health and Nutrition Examination Survey added an important nuance: self-reported osteoarthritis showed no link with dying earlier, but radiographic knee osteoarthritis was tied to higher cardiovascular and diabetes-related mortality.³

A more recent meta-analysis of observational studies clarified the picture further. Symptomatic osteoarthritis and knee or foot osteoarthritis were associated with a meaningfully higher risk of dying, while radiographic osteoarthritis alone (visible joint damage on an X-ray but no reported pain) was not.⁴ This distinction matters because it suggests the mortality risk comes less from the structural damage to the joint and more from what that damage does to a person’s daily life, especially their ability to stay active.

Which Joints Carry the Most Risk

Not all osteoarthritis is equal when it comes to life expectancy. When researchers separate the data by joint, hand osteoarthritis appears to be nearly harmless from a mortality standpoint. In fact, one systematic review with meta-analysis found that when hand osteoarthritis data was excluded, the remaining osteoarthritis cases showed a significant 18 percent increase in mortality risk.⁵ The explanation is intuitive: sore hands do not stop you from walking, but a painful knee or hip does.

Knee and hip osteoarthritis both appear to raise the risk of dying from cardiovascular causes specifically. One large study found that cardiovascular death risk increased to about 19 percent higher for knee osteoarthritis and 13 percent higher for hip osteoarthritis over roughly a decade of follow-up, driven mostly by chronic ischemic heart disease and heart failure.⁶ Another meta-analysis looking specifically at knee osteoarthritis found that the combination of radiographic changes plus symptoms was associated with about a 58 percent higher mortality risk, while either radiographic changes alone or symptoms alone carried smaller and less certain elevations.⁷

The Cardiovascular Connection

The single biggest pathway between osteoarthritis and earlier death runs through the heart. A meta-analysis of observational studies found that people with osteoarthritis had roughly a 24 percent higher risk of cardiovascular disease compared to the general population, with particularly strong associations for ischemic heart disease, heart failure, and cardiovascular death.⁸ Stroke risk was modestly elevated but did not reach statistical significance in that analysis.

Several mechanisms appear to link the two conditions. Shared low-grade chronic inflammation is one plausible explanation; the same inflammatory molecules circulating in osteoarthritis joints also promote arterial plaque buildup.⁹ The connection seems to be stronger in women. A population-based cohort study found that in females specifically, osteoarthritis was associated with higher systemic inflammation, and that inflammation in turn raised cardiovascular disease risk, with an effect size of about 77 percent higher risk among women with elevated inflammatory markers.¹⁰ Even after accounting for standard cardiovascular risk factors, though, osteoarthritis still carried some unexplained additional risk, suggesting we have not fully identified every mechanism at work.

Reduced Walking Is the Biggest Mediator

If you are looking for the single most important reason osteoarthritis shortens lives, it is probably this: people with painful joints walk less. A path analysis study that traced the routes connecting osteoarthritis to mortality found that low walking frequency was the strongest indirect pathway. Depression, unrefreshed sleep, and anxiety also contributed, but the effect of walking frequency was the most pronounced, and when walking frequency was included as a mediating variable, the direct effect of osteoarthritis on mortality shrank considerably.¹¹

This finding has real practical implications. It suggests that interventions keeping people with osteoarthritis physically active, whether through pain management, physical therapy, assistive devices, or exercise programs adapted to joint limitations, could meaningfully reduce the mortality risk associated with the disease. The threat is not the worn cartilage itself but the sedentary spiral that chronic joint pain tends to trigger.

Depression and Sleep Make Things Worse

Beyond reduced mobility, osteoarthritis feeds into mental health problems that carry their own mortality risks. One cohort study found that osteoarthritis was positively associated with depression, and that depression partly mediated the link between osteoarthritis and cardiovascular death, accounting for roughly 6 percent of that association.¹² Six percent sounds small, but depression also amplifies other risk factors. Another study found that among osteoarthritis patients, those with depression had a stronger link between systemic inflammation and all-cause mortality than those without depression.¹³

Sleep disturbance adds another layer. A study of older adults with osteoarthritis found that baseline sleep problems predicted functional decline over a year, independent of both pain levels and depressive symptoms.¹⁴ Functional decline feeds back into reduced physical activity, which as we have seen is the strongest pathway to earlier death. The reinforcing loop of pain, poor sleep, worsening function, and depression makes osteoarthritis harder to manage as it progresses.

Pain Medications Carry Their Own Cardiovascular Risks

One of the more troubling aspects of the osteoarthritis-mortality relationship is that some of the treatments for joint pain may themselves increase cardiovascular risk. A nationwide Danish study of over half a million osteoarthritis patients found that every commonly used NSAID was associated with a higher risk of cardiovascular events compared to no NSAID use. The risk varied by drug: rofecoxib carried the highest elevation, followed by celecoxib and diclofenac, while ibuprofen and naproxen had smaller but still significant increases.¹⁵ A separate trial focused on high-cardiovascular-risk patients suggested that ibuprofen may increase clotting and heart failure events among aspirin users compared to some other options.¹⁶

A large U.S. Veterans study painted a more complicated picture: NSAID exposure was actually associated with lower all-cause mortality in both groups with and without coronary artery disease, even though it raised the risk of cardiovascular or cerebrovascular events specifically.¹⁷ The likely explanation involves healthy-user bias: people well enough to take NSAIDs regularly tend to be healthier overall than people whose conditions preclude their use. The cardiovascular safety question remains one where individual context matters enormously.

Opioid-like painkillers raise a different alarm. A study published in JAMA found that osteoarthritis patients prescribed tramadol had nearly double the mortality rate of those prescribed naproxen over a one-year follow-up, with the greatest elevation in the first three months. Tramadol was also associated with higher mortality compared to diclofenac.¹⁸ When tramadol was compared specifically to codeine in a meta-analysis, however, no significant difference in mortality emerged, which suggests the risk may be more about the class of medication and the population that receives it than about tramadol uniquely.¹⁹

Joint Replacement and Survival

For people with severe osteoarthritis, total joint replacement is often presented as a life-improving surgery. It turns out it may also be life-extending, at least for a while. A population-based study found that survival after both total hip and total knee replacement was significantly better than expected for the general population, with roughly an 18 to 20 percent lower death rate in the years following surgery.²⁰ A Danish study of total hip replacement patients found similarly reduced long-term mortality compared to controls.²¹

The survival advantage is not permanent, though. The population-based study showed that the death rate after total knee replacement was as low as half that of the general population in the first year, but it climbed steadily and actually became worse than the general population beyond 18 years after surgery.²⁰ Another study confirmed this pattern, showing significantly lower mortality for the first decade after knee replacement, but a reversal that became more pronounced after 20 years.²² The initial boost likely reflects both a “healthy survivor” effect (sicker patients are screened out before surgery) and the restored mobility that allows people to be more physically active. The late-stage reversal likely reflects the aging population catching up with complications and the limits of prosthetic joints.

The Metabolic Overlap

Osteoarthritis and conditions like obesity, diabetes, and high blood pressure share so many risk factors that untangling which one is actually causing the mortality increase is genuinely difficult. Researchers now recognize a “metabolic phenotype” of osteoarthritis where the disease is driven not just by mechanical wear but by metabolic dysfunction, chronic low-grade inflammation, and hormonal imbalances.²³ A 20-year follow-up study of patients after hip or knee replacement found that cardio-metabolic risk factors were associated with bilateral osteoarthritis and lower long-term survival, reinforcing the need to aggressively manage metabolic health in people with osteoarthritis.²⁴

Emerging research on the gut microbiome adds another dimension. High-fat diets can disrupt the balance of gut bacteria, weakening the intestinal barrier and allowing inflammatory molecules into the bloodstream, which are the same pro-inflammatory cytokines found in osteoarthritic joints.²⁵ Omega-3 fatty acids may help restore a healthier gut bacterial balance and reduce some of this inflammation, though the research on whether that translates into lower mortality for osteoarthritis patients specifically is still early.²⁶

Falls and Frailty in Older Adults

For older adults, osteoarthritis contributes to mortality risk through a pathway that does not get enough attention: falls. Knee osteoarthritis weakens the muscles around the joint, reduces balance, and limits the ability to catch yourself when you stumble. When knee osteoarthritis coexists with sarcopenia (the age-related loss of muscle mass), the combination roughly quadruples the odds of having recurrent falls compared to having neither condition.²⁷ Falls are a leading cause of injury-related death in people over 65, so this pathway from osteoarthritis to instability to falls is worth taking seriously, especially for people who are already frail.

Socioeconomic Disparities in Outcomes

The mortality implications of osteoarthritis are not evenly distributed across populations. Lower education and nonprofessional occupations are both linked to worse arthritis outcomes, including more pain, worse function, and slower recovery.²⁸ Higher community poverty rates are associated with worse pain and disability among people with knee osteoarthritis, creating a feedback loop where the people least able to afford treatment are the ones suffering the most.²⁹

Access to joint replacement, one of the interventions that appears to extend survival, is unequal as well. Black patients, Hispanic patients, and patients with lower socioeconomic status are less likely to undergo total joint replacement than white patients or wealthier patients, and when they do receive surgery, they tend to have worse functional outcomes and more complications.³⁰ These disparities mean that the mortality burden of osteoarthritis falls disproportionately on people who already face structural disadvantages in health care. For these populations, the modest average mortality risk from osteoarthritis likely understates the real impact.